Search: WFRF:(Pettersson Frida Ekholm)
> (2005-2009) >
An amyloid-beta pro...
An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
-
- Lord, Anna (author)
- Uppsala universitet,Geriatrik
-
- Gumucio, Astrid (author)
- Uppsala universitet,Geriatrik
-
- Englund, Hillevi (author)
- Uppsala universitet,Geriatrik
-
show more...
-
- Sehlin, Dag (author)
- Uppsala universitet,Geriatrik
-
Sundquist, Valentina Screpanti (author)
-
Söderberg, Linda (author)
-
Möller, Christer (author)
-
Gellerfors, Pär (author)
-
- Lannfelt, Lars (author)
- Uppsala universitet,Geriatrik
-
- Pettersson, Frida Ekholm (author)
- Uppsala universitet,Geriatrik
-
- Nilsson, Lars N G (author)
- Uppsala universitet,Geriatrik
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2009
- 2009
- English.
-
In: Neurobiology of Disease. - : Elsevier BV. - 0969-9961 .- 1095-953X. ; 36:3, s. 425-434
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Human genetics link Alzheimer's disease pathogenesis to excessive accumulation of amyloid-beta (Abeta) in brain, but the symptoms do not correlate with senile plaque burden. Since soluble Abeta aggregates can cause synaptic dysfunctions and memory deficits, these species could contribute to neuronal dysfunction and dementia. Here we explored selective targeting of large soluble aggregates, Abeta protofibrils, as a new immunotherapeutic strategy. The highly protofibril-selective monoclonal antibody mAb158 inhibited in vitro fibril formation and protected cells from Abeta protofibril-induced toxicity. When the mAb158 antibody was administered for 4 months to plaque-bearing transgenic mice with both the Arctic and Swedish mutations (tg-ArcSwe), Abeta protofibril levels were lowered while measures of insoluble Abeta were unaffected. In contrast, when treatment began before the appearance of senile plaques, amyloid deposition was prevented and Abeta protofibril levels diminished. Therapeutic intervention with mAb158 was however not proven functionally beneficial, since place learning depended neither on treatment nor transgenicity. Our findings suggest that Abeta protofibrils can be selectively cleared with immunotherapy in an animal model that display highly insoluble Abeta deposits, similar to those of Alzheimer's disease brain.
Keyword
- Alzheimer's disease
- Immunotherapy
- Monoclonal antibody
- Soluble amyloid-beta
- Intraneuronal
- Transgenic mice
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Lord, Anna
-
Gumucio, Astrid
-
Englund, Hillevi
-
Sehlin, Dag
-
Sundquist, Valen ...
-
Söderberg, Linda
-
show more...
-
Möller, Christer
-
Gellerfors, Pär
-
Lannfelt, Lars
-
Pettersson, Frid ...
-
Nilsson, Lars N ...
-
show less...
- Articles in the publication
-
Neurobiology of ...
- By the university
-
Uppsala University